Liquid Biopsy Supports Precision Oncology
Experts highlight clinical value, workflow integration, and real-world impact in lung and breast cancer diagnostics
Clinical Scorecard: Liquid Biopsy Supports Precision Oncology
At a Glance
Category Detail
Condition Lung and Breast Cancer Key Mechanisms Circulating tumor DNA (ctDNA) analysis for genomic profiling Target Population Patients with insufficient tumor tissue for testing Care Setting Oncology clinics and diagnostic pathways
Key Highlights
Liquid biopsy offers earlier molecular insights and faster turnaround times. ctDNA analysis captures tumor heterogeneity and resistance mechanisms. Integration into lung cancer pathways reduced time to treatment allocation significantly. In breast cancer, ctDNA testing identified actionable variants in 46% of patients. Liquid biopsy complements tissue testing, enhancing access to targeted therapies. Guideline-Based Recommendations
Diagnosis
Utilize liquid biopsy for patients with limited tissue availability. Management
Incorporate ctDNA analysis into treatment decision-making processes. Monitoring & Follow-up
Use liquid biopsy to monitor tumor evolution and resistance. Risks
Be aware of analytical challenges such as clonal hematopoiesis. Patient & Prescribing Data
Patients with lung and breast cancer requiring genomic profiling.
Liquid biopsy can identify actionable variants earlier than tissue testing.
Clinical Best Practices
Integrate ctDNA testing early in the diagnostic pathway. Ensure advanced bioinformatics are in place to interpret ctDNA results. Monitor ctDNA levels to assess treatment response and resistance. References
